Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High – Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reached a new 52-week high on Thursday . The stock traded as high as $3.42 and last traded at $3.37, with a volume of 932558 shares. The stock had previously closed at $3.34.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Stock Up 3.3 %

The firm has a market cap of $517.03 million, a price-to-earnings ratio of -8.07 and a beta of 2.70. The business’s fifty day moving average is $2.96 and its two-hundred day moving average is $2.49.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same quarter last year, the business posted ($0.14) earnings per share. Research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Simplicity Wealth LLC bought a new position in shares of Xeris Biopharma during the second quarter worth $27,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xeris Biopharma during the third quarter worth $35,000. Allspring Global Investments Holdings LLC boosted its position in shares of Xeris Biopharma by 4,512.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after purchasing an additional 15,929 shares in the last quarter. Bayesian Capital Management LP bought a new position in shares of Xeris Biopharma during the first quarter worth $37,000. Finally, Asset Management Group Inc. boosted its position in shares of Xeris Biopharma by 130.7% during the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock worth $60,000 after purchasing an additional 15,000 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.